Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.90 -2.2% 40.10 40.10 40.60 40.60 40.00 40.60 37,204 13:05:49
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 11.6 182

Ekf Diagnostics Share Discussion Threads

Showing 4151 to 4174 of 4475 messages
Chat Pages: Latest  167  166  165  164  163  162  161  160  159  158  157  156  Older
DateSubjectAuthorDiscuss
10/3/2022
10:29
Food for thought - We know from EKF's first half results that their major industrial partner represented less than half of their contract manufacturing revenues for PrimeStore MTM and PBS for the first half of 2021, and that EKF had already seen a shift to a wider mix of revenues from a broader customer base. With EKF expecting to see the share of revenue contribution from other customers continue to rise as they move through the year. In addition, with the expectation that sales of these products will continue for the foreseeable future, EKF added two further factory units to their existing site in Cardiff which was opened in January, and have added off-site manufacturing space in Boerne in the US. From EKF's Update to Growth Plan - 2. Contract Manufacturing: Molecular diagnostics and other applications a) Continued expansion of contract manufacturing facilities in UK and USA b) Demand for manufacturing services driving new opportunities for non-COVID related products. c) Increased production of components and kits to support COVID sample collection to meet demand from new customers hTTps://www.ekfdiagnostics.com/res/Interims%202021%20v.7.pdf There was good reason why phosphate buffer solution (PBS) was introduced by EKF, not least that the inactivation ingredients within PrimeStore MTM is considered hazardous to humans or the environment and is therefore not used in direct-to-consumer testing (which uses PBS). MTM can also potentially interact with bleach and other cleaning products used to clean down lab equipment which in turn could release toxic cyanide gas, ultimately limiting the use of PrimeStore MTM to labs where the cleaning protocols do not require bleach (which still represents a large section of the market). One of my main thrusts in my post 2582, was that there is a more specialised area too, in terms of extraction/lysis buffers etc. And with EKF's Chief Scientific Officer, Luke Daum, who has a lot of experience, and indeed IP, in developing and formulating such products, could mean this might also be an area to watch. In other words, such specialised areas, e.g. where there is obviously a need for an effective inactivating media that is not hazardous, might also provide for a decent opportunity. In this regard, I note the recent news from Thermo Fisher for new Non-hazardous Viral Inactivation Media (not yet available in the US) - New Non-Hazardous Viral Inactivation Medium Supports Safe Collection and Transport of SARS-CoV-2 Breakthrough formulation helps reduce the risk of exposure using anon-hazardous formulation and leakproof format during transport and processing BASINGSTOKE, UK (March 8, 2022) – A new viral transport medium that enables collection and rapid inactivation of the SARS-CoV-2 virus, and stabilizes viral RNA at ambient temperature for transportation and use in in vitro diagnostic testing procedures, is now available in Europe. Full release - hTTps://corporate.thermofisher.com/content/tfcorpsite/us/en/index/newsroom/press-releases/2022/Mar/08-New-Non-Hazardous-Viral-Inactivatio-Medium-Supports-Safe-Collection-and-Transport-of-SARS-CoV-2.html
wan
09/3/2022
07:38
Luke Daum Chief Scientific Officer at EKF Diagnostics 9th March 2022 I am pleased to announce that #EKF Diagnostics and YourGene are stepping up to launch the first ever #NIPT testing pipeline in the USA at our CLIA certified ADL Health testing laboratory in San Antonio, Texas. Dr. Luke Daum (EKF CSO) and the ADL Health team prepare the first #NGS run. It’s been a great week working with our friends from YourGene and growing our service test menu to include important noninvasive prenatal testing for Downs Syndrome (trisomy 21), Edwards Syndrome (trisomy 18), and Palau Syndrome (trisomy 13) using Illumina NGS. hTTps://www.linkedin.com/posts/luke-daum-01661_ekf-nipt-ngs-activity-6907195780751327232-7R3N
wan
07/3/2022
09:47
Time is already telling us pal - don't you see you are surrendering all paper profits you thought was yours?43 printing (only 10 points away from my 33 target). PS. Maths 101: if one is down 50% you will need +100% just to get back to break even. No small feat for a few on here of course... gm - how are you these days?
tongosti
07/3/2022
08:00
Today's news duly noted. Fwiw, at what is clearly a very difficult and challenging time, I think the investment in Verici will deliver above most private investor expectations. Time will tell!
wan
06/3/2022
08:26
Numerous publications have been running stories around testing nearer the patient, including within hospitals, doctors' surgeries, and in patients' homes for multiple illnesses/viruses (with some utilising one sample to test for multiple viruses), regarding how this area in particular is likely experience significant growth over the coming years, and is likely to form a significant part of how we see healthcare evolve and grow beyond, and as a consequence, of the pandemic. These tests will be centred predominantly around PCR (e.g. rapid or home sample collection) and lateral flow type tests, both of which utilise Phosphate Buffered Saline (PBS), or derivatives of that. The fact is, the buffer solution used in many lateral flow tests consists of 99.7% saline solution. Therefore, in my view there are more opportunities for EKF's PBS manufacturing capability, than PCR testing alone. Indeed, PBS (and more specialised buffer solutions), is applicable to a multitude of tests and test 'kits'. The other substances contained in the buffer solution are important (possibly differentiating the test) but are obviously very low in concentration. The concentrations of those ingredients in the buffer solution are far below the threshold applicable in UK and European hazardous substance regulations, so they do not usually present for concerns when used as an integral part of testing, including tests used directly by the patient. There is an even more specialised area too, in terms of extraction/lysis buffers etc. And with EKF's Chief Scientific Officer, Luke Daum, who has a lot of experience in developing such products, this might also be an area to watch. With the US, Europe and the UK (amongst others) committed to sustaining and supporting the growth of a strong 'domestic' diagnostic manufacturing base (becoming less reliant on China) in order to be better prepared for the next pandemic, and emergency responses to other health threats, such as surge testing and surveillance etc, this backdrop is also likely to at least provide a solid secure base for diagnostic manufacturers, especially those who have already demonstrated they are capable. In short, EKF Diagnostics supply and manufacture test kit components, collation of test kits, and also provide high-throughput laboratory testing to results, and are therefore well placed to address this new era of diagnostics. An era where people are empowered to understand their own health in the comfort and privacy of their homes, which will also include consumer-initiated lab testing, and is likely to represent a paradigm shift, in turn offering a very large global growth opportunity for non-COVID related products. Overall, and in my view only, the above and EKF's existing diagnostic business should prove to be a winning combination that addresses a substantial growth opportunity!
wan
05/3/2022
06:00
Tongosti...I don't ramp, and I don't post to get a thumbs up, or even a thank you. But I also accept I can be wrong in my judgements and assessments. But just like you, I won't prove to be right, or indeed wrong all of the time! Staying with the backdrop/ direction of travel theme, and a share tip - How Covid-19 changed biotechnology – and how you can invest The pandemic has exacted a huge human and financial toll, but it has also transformed scientific research in ways that will deliver huge benefits for healthcare. Matthew Partridge reports. by: Dr Matthew Partridge 4 MAR 2022 The entire diagnostics industry, from large firms such as Abbott Laboratories to smaller domestic laboratories, has benefited from a “surge in demand”, adds Hermann. Some of this may be about to tail off, but the outlook remains bright. Governments around the world have realised “the importance of having a diagnostics infrastructure in place” to protect against the next pandemic – and to prevent them becoming too dependent on countries like China for supplies. Overall, biotech achievements over the last two years have “created a spate of exciting potential investment opportunities”, say Thomson and Zhang. “Strong growth prospects” are set to “continue into 2022 and beyond”. Below, we look at some ways to invest. The need to maintain some domestic testing infrastructure in the UK is good news for EKF Diagnostics (LSE: EKF), says Stifel’s Herrmann. It was one of the few British companies to successfully develop and market a Covid-19 test, but already had a reputation as a manufacturer of diagnostic devices, mainly centred around analysis of blood. Between 2015 and 2019, its sales grew by more than half and Covid-19 further boosted its growth. It trades at 14 times 2022 earning and pays a dividend yield of 2.3%. Full article - hTTps://moneyweek.com/investments/stocks-and-shares/biotech-stocks/604533/how-covid-19-changed-biotechnology-and-how-you
wan
04/3/2022
14:44
Direction of travel - that's a good one. Think your chart must be upside down. Incidentally, one never sees thank you posts following incessant ramping on this board any longer. Now, that's some major reversal in the direction of travel. Lol
tongosti
04/3/2022
11:50
Backdrop/direction of travel - Press release 10 February 2022, Brussels The new European Health Emergency Preparedness and Response Authority (HERA) today presents its first annual work plan, which will have a budget of €1.3 billion in 2022 to prevent, prepare for and rapidly respond to cross-border health emergencies. Following the adoption of the 2022 work plan by the HERA Board, HERA can now start implementing actions to strengthen preparedness and response capabilities within the EU, address vulnerabilities and strategic dependencies and contribute to reinforcing the global health emergency architecture. Prevent and prepare for future cross border health emergencies: In the “preparedness phase”, HERA will work closely with other EU and national health agencies, industry, research community, civil society and international partners to improve the EU's readiness for future health emergencies. Actions include: Procuring and stockpiling medical countermeasures for a series of public health threats with a budget of over €580 million; Releasing over €300 million to research and development of medical countermeasures and innovative technologies against emerging threats; Building a network of ever-warm manufacturing facilities that can be mobilised in case of emergency (EU FAB); Establishing a long term and large scale EU platform for clinical trials and data platforms; Identifying three high-impact health threats, in addition to COVID-19, by the end of spring in close collaboration with Member States in the HERA Board, EU agencies, international partners and experts. Detect future health threats: HERA will in addition carry out threat assessments and intelligence gathering, develop models to forecast an outbreak, and map out a response plan at EU level. Actions for 2022 include: Putting in place a state of the art real-time health threat detection and intelligence system; Creating a dedicated IT platform for threat assessment and threat prioritisation. Respond to health threats: In the context of the response to the COVID-19 pandemic, HERA's emergency response functions have already been activated. In the event of further cross-border public health emergencies at EU level, additional action will be taken, notably by activating emergency funding and launching mechanisms for monitoring, new targeted development, procurement and purchase of medical countermeasures and raw materials. Ongoing actions include: Ensuring the timely provision of COVID-19 vaccines to EU Member States, including variant-adapted vaccines if needed; Procurement of COVID-19 therapeutics for EU Member States; Scaling up national capacities for the detection and scientific assessment of variants; Ensuring delivery of vaccines across the world. hTTps://ec.europa.eu/commission/presscorner/detail/en/ip_22_928
wan
04/3/2022
11:38
Backdrop/direction of travel - Public Health Supply Chain and Industrial Base One-Year Report (February 2022). Worth reading in its entirety, with section on Testing & Diagnostics​, Public Health Supply Chain and Industrial Base One-Year Report​, making for particularly interesting read - Ensure COVID-19 Testing Capacity: The U.S. Government will continue to invest to ensure sufficient COVID-19 testing capacity. It will accomplish this through stockpiling tests and testing supplies while simultaneously working closely with the industrial supply chain. HHS will prioritize warm-base production capacity that will allow test, component, and reagent suppliers to quickly scale up production during surges in demand. The U.S. Government is also planning investments to help reduce the costs of tests, broaden detection capabilities to include multiple viruses and pathogens, increase production, and make tests more widely available. The U.S. Government plans to invest further in training and human capital. Fortifying a robust testing and diagnostics supply chain will ensure that tests and diagnostics are ready to be developed, deployed, and analyzed during future public health emergencies.​​​​​​​;​​̴3; U.S. Department of Health and Human Services (HHS) - hTTps://aspr.hhs.gov/MCM/IBx/2022Report/Pages/default.aspx
wan
04/3/2022
11:30
Backdrop/direction of travel - US National COVID-⁠19 Preparedness Plan Today, the U.S. government is releasing the National COVID-19 Preparedness Plan – which will enable America to move forward safely, sustaining and building on the progress we’ve made over the past 13 months. This plan lays out the roadmap to help us fight COVID-19 in the future as we begin to get back to our more normal routines. We look to a future when Americans no longer fear lockdowns, shutdowns, and our kids not going to school. It’s a future when the country relies on the powerful layers of protection we have built and invests in the next generation of tools to stay ahead of this virus. Prepare for New Variants Before January 2021, the federal government had insufficient data and sequencing capabilities and was ill-equipped to respond to new variants. Electronic case reporting was in place for only a handful of states in 2020 and the country could sequence only 3,000 viral isolates per week. America had no plan for responding to a new variant or standing up comprehensive efforts to respond to a surge in COVID-19 cases. The Administration has enhanced our collection, production, and analysis of data, and expanded electronic case reporting to all 50 states, Washington D.C., Puerto Rico, and thousands of health care facilities. The CDC now tracks a range of key COVID-19 response metrics including cases, tests, vaccinations, and hospital admissions in real-time. Additionally, the CDC launched – and is continually enhancing – the National Wastewater Surveillance System (NWSS) to track the presence of SARS-COV-2 in wastewater samples collected across the country. And America has established a world-class sequencing operation, sequencing up to 90,000 isolates a week. The CDC’s sequencing efforts can now reliably detect variants that account for as little as 0.1% of all COVID-19 cases circulating in the United States. And when new variants are identified, the federal government has a network of researchers – federal, academic, and commercial – who are able to study the sequence and assess mutations rapidly, allowing the government to respond quickly to concerning variants. Full details - hTTps://www.whitehouse.gov/covidplan/
wan
04/3/2022
11:10
Backdrop/direction of travel - UK government to provide £260m for life sciences manufacturing 3 MARCH 2022 A further £60 million will be available to support commercial-scale manufacturing investments by companies developing a range of technologies including medical devices and diagnostics, and cell and gene therapies. Commenting on the announcement, BIVDA CEO Doris-Ann Williams MBE, said: “Building a diagnostics sector of critical mass requires supportive policymaking and funding allocation. We welcome today’s innovation research investment and the LSIMF from the Government as steps towards boosting the UK’s crucial diagnostic output.” Full story - hTTps://www.med-technews.com/news/medtech-merger-acquisition-finance-and-investment-news/uk-government-to-provide-260m-for-life-sciences-manufacturi/
wan
04/3/2022
09:01
A next to nothing dividend yield is very important when the share price has collapsed 50%....Really?!?!
tongosti
04/3/2022
08:00
Verici has announced a fundraise this morning! It certainly reads well, and details a strong rationale for an accelerated strategy. I note Chris Mills is also participating as is EKF. More dividends - I further note that EKF intends that any new ordinary shares received as a result of its participation in the Fundraise will be distributed to its own underlying shareholders along with EKF's existing shareholding in the Company as soon as reasonably practicable and subject to appropriate arrangements to maintain an orderly market in Verici's shares following such distribution. https://uk.advfn.com/stock-market/london/verici-dx-VRCI/share-news/Verici-Dx-PLC-Proposed-Fundraise/87462198
wan
01/3/2022
09:17
South of 48 printing.
tongosti
28/2/2022
15:58
James...I duly noted IIG's announcement, and if it was going to affect Julian's roll, then I am sure we would have been notified. What I also noted from that announcement was the the following - 'During his tenure at EKF, Julian successfully completed multiple fundraisings, spinouts and the acquisition and subsequent integration of eight businesses in seven countries, building revenue from zero to over GBP70 million.' EKF's 2020 F/Y revenues was £65.3m, with 2021 FY Results due next month.
wan
28/2/2022
15:34
Intuitive Investments Group (IIG) issued an RNS last Friday in which it announced that Julian Baines has stepped up to become the non-executive chairman. He was previously only on IIG's advisory panel. So, it is a non-exec role and as such my working assumption is that it will not affect his ongoing strategic role at EKF in relation to the Mount Sinai group, but it might.
james188
28/2/2022
10:20
With 48 target being reached, facts on the ground indicate that this is heavily oversold at this stage. It does not mean the pain is over (my base case is for 33 to be next) but it does mean that (unless wider markets tank from here which is a very high probability at the moment) some meaningful consolidation / dead cat bounce is due.
tongosti
21/2/2022
15:32
Brokers are paid cheerleaders with no skin in the game. Folks should do their own research - after all it's their money ain't it.
tongosti
21/2/2022
14:34
Importantly, and as I indicated previously, EKF have communicated their growth plan, and it is clear to me that they are executing against it. Nonetheless, I appreciate we are in flux, as it would appear that quite a lot is being reconsidered (or simply unknown) by the markets, and I note that we are now circa 40% below the recent Brokers reiterated Buy recommendation and Target Price of 86p.
wan
21/2/2022
14:11
n isolation fundamentals look great (sales gwth / eps gwth / and profit margins is what I typically look at). Key word "in isolation". Broadly speaking, I never pay attention to any fundamentals UNLESS the market is in synch with them. Whichever way I cut it, I only make money by being on the right side of the market not by arguing with him. Am saying this because if fundamentals are indeed so strong then the share price should follow suit. Actually it did (about 400% in the run up to 80+) but those fundamentals were all discounted in a great hurry. Have spoken about this several times I guess. As for a quick review of my reasons behind my bearishness here please see my post 2541Cheers and good luck.
tongosti
21/2/2022
13:56
Congratulations?!?!
tongosti
21/2/2022
08:10
Edit to the above post - Congratulations and well-deserved!
wan
21/2/2022
07:57
EKF's diabetes products delivered over £19m of revenues in 2020 (down on the previous year (£20.6m) due to the pandemic). The diabetes product portfolio 'currently' includes - BiosenTM - hTTps://www.ekfdiagnostics.com/biosen-analyzer.html Quo-LabĀ® A1c - hTTps://www.ekfdiagnostics.com/quo-lab.html Quo-TestĀ® A1c - hTTps://www.ekfdiagnostics.com/quo-test.html STAT-Site WB - hTTps://www.ekfusa.com/analyzers/stat-site-wb/ β-Hydroxybutyrate LiquiColor - hTTps://www.ekfusa.com/chemistry_range/beta-hydroxybutyrate/ I have noted and been watching EKF's recruitment drive and efforts, which I have found to be a useful guide generally. The following recently caught my attention regarding a new hire and the attached title - William Shorter Global Product Manager - Diabetes Diagnostics at EKF Diagnostics hTTps://www.linkedin.com/in/william-shorter-9292a843/ Which coincides with the promotion of Gavin Jones (9yrs at EKF) from Global Head of product Management to - Managing Director, UK Managing Director, UK Full-time Feb 2022 - Present United Kingdom Cardiff, Wales, United Kingdom Provide strategic advice to the board of directors, plan cost-effective business strategies and develop new ideas based on market and industry. Establish company goals aligned with the board and shareholders. Implement company policies and ensure compliance. Maintain and monitor budgets ensuring efficient financial operation. Provide leadership to personnel from executive level downwards. Oversee day-to-day operations to meet business needs. hTTps://www.linkedin.com/in/gavin-jones-48297b23/?originalSubdomain=uk Congratulations and well-deserved!
wan
21/2/2022
02:41
tongosti sorry if you have already mentioned why do you think this is getting oblitered looks like your 48p was spot on but so painful that your proving to be correct but what is your views on the fundamentals of the business?
az4hr
Chat Pages: Latest  167  166  165  164  163  162  161  160  159  158  157  156  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220929 12:24:39